Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.
2.

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.

Sun CH, Chang YH, Pan CC.

Histopathology. 2011 Jun;58(7):1054-63. doi: 10.1111/j.1365-2559.2011.03856.x.

PMID:
21707707
3.
4.

Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.

Fadare O, Renshaw IL, Liang SX.

Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):352-9. doi: 10.1097/PAI.0b013e3182013441.

PMID:
21285872
5.

Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.

Ünver NU, Acikalin MF, Öner Ü, Ciftci E, Ozalp SS, Colak E.

Arch Gynecol Obstet. 2011 Aug;284(2):483-90. doi: 10.1007/s00404-010-1690-z. Epub 2010 Sep 28.

PMID:
20878171
6.

ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.

Hu LY, Sun ZG, Wen YM, Cheng GZ, Wang SL, Zhao HB, Zhang XR.

Neuroscience. 2010 Sep 1;169(3):1046-62. doi: 10.1016/j.neuroscience.2010.05.046. Epub 2010 Jun 1.

PMID:
20678995
7.

Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications.

Ong KW, Teo M, Lee V, Ong D, Lee A, Tan CS, Vathsala A, Toh HC.

Clin Cancer Res. 2009 Sep 1;15(17):5350-8. doi: 10.1158/1078-0432.CCR-08-2979. Epub 2009 Aug 25.

8.

Epithelioid smooth muscle tumors of the uterus do not express CD1a: a potential immunohistochemical adjunct in their distinction from uterine perivascular epithelioid cell tumors.

Fadare O, Liang SX.

Ann Diagn Pathol. 2008 Dec;12(6):401-5. doi: 10.1016/j.anndiagpath.2008.04.009. Epub 2008 Jul 7.

PMID:
18995203
9.

Use of myocardin in the classification of mesenchymal tumors of the uterus.

Liang J, Wu L, Xiao H, Li N, Wang H, Cheng C, Bai R, Zhao Y, Zheng H.

Int J Gynecol Pathol. 2010 Jan;29(1):55-62. doi: 10.1097/PGP.0b013e3181b1cdb0.

PMID:
19952936
10.

Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.

Darb-Esfahani S, Faggad A, Noske A, Weichert W, Buckendahl AC, Müller B, Budczies J, Röske A, Dietel M, Denkert C.

J Cancer Res Clin Oncol. 2009 Jul;135(7):933-41. doi: 10.1007/s00432-008-0529-5. Epub 2008 Dec 24.

PMID:
19107520
11.

An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.

Allen MM, Douds JJ, Liang SX, Desouki MM, Parkash V, Fadare O.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2795-801. eCollection 2015.

12.

Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.

Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T.

Mol Carcinog. 2008 Jun;47(6):446-57.

PMID:
18058806
13.

Lack of correlation between leptin receptor expression and PI3-K/Akt signaling pathway proteins immunostaining in endometrioid-type endometrial carcinomas.

Bogusiewicz M, Semczuk A, Gogacz M, Skomra D, Jakowicki JA, Rechberger T.

Cancer Lett. 2006 Jul 8;238(1):61-8. Epub 2005 Aug 8.

PMID:
16085355
15.

Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.

Sgantzos MN, Galani V, Arvanitis LD, Charchanti A, Psathas P, Nakou M, Havaki S, Kallioras V, Marinos E, Vamvakopoulos NC, Kittas C.

Pathol Res Pract. 2007;203(1):31-7. Epub 2006 Nov 28.

PMID:
17129677
16.
17.

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.

Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A.

Clin Cancer Res. 2008 May 1;14(9):2673-80. doi: 10.1158/1078-0432.CCR-07-1046.

18.

Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.

Winter WE 3rd, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS, Birrer MJ.

Gynecol Oncol. 2003 Oct;91(1):3-8.

PMID:
14529656
19.

Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer.

Oh MH, Lee HJ, Yoo SB, Xu X, Choi JS, Kim YH, Lee SY, Lee CT, Jheon S, Chung JH.

Virchows Arch. 2012 Jun;460(6):601-9. doi: 10.1007/s00428-012-1239-6. Epub 2012 May 5.

PMID:
22562131
20.

Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.

Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang LS.

Otol Neurotol. 2008 Jan;29(1):58-68. doi: 10.1097/mao.0b013e31816021f7.

PMID:
18199958

Supplemental Content

Support Center